John Maraganore, the former CEO of Alnylam Therapeutics turned biotech elder statesman and venture capitalist, is launching a new startup that he hopes can expand
Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup led by a chief
DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new
ARCH Venture Partners has raised $3 billion for a new fund — one of the largest in the biotech industry, and one the VC firm
Serial biotech founder George Church has a new startup, and this time, he has skin in the game, quite literally. Church, the enigmatic founder behind
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth
After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop autoimmune
Novartis is opening a new manufacturing facility in California and expanding an existing production site in its bid to dominate the booming radiopharmaceuticals field amid
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped
Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The